Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.

Authors :: Seung KJ
Khan P
Franke MF
Ahmed S
Aiylchiev S
Alam M
Putri FA
Bastard M
Docteur W
Gottlieb G
Hewison C
Islam S
Khachatryan N
Kotrikadze T
Khan U
Kumsa A
Lecca L
Tassew YM
Melikyan N
Naing YY
Oyewusi L
Rich M
Wanjala S
Yedilbayev A
Huerga H
Mitnick CD
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2020 Jul 11; Vol. 71 (2), pp. 415-418.
Publication Year :: 2020
Abstract: Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.<br /> (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)

Subjects :: Antitubercular Agents therapeutic use
Humans
Oxazoles therapeutic use
Treatment Outcome
Mycobacterium tuberculosis
Nitroimidazoles therapeutic use
Tuberculosis, Multidrug-Resistant drug therapy

Language :: English
ISSN :: 1537-6591
Volume :: 71
Issue :: 2
Database :: MEDLINE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publication Type :: Academic Journal
Accession number :: 31676905
Full Text :: https://doi.org/10.1093/cid/ciz1084

Full Text Access

Tools